Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaos Corporation (DAC) vs Novo Nordisk A/S (NVO) Price & Performance

Danaos CorporationTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Danaos Corporation vs Novo Nordisk A/S — how do they compare? Danaos Corporation trades at $135.01 (market cap $2.52B), while Novo Nordisk A/S trades at $45.84 (market cap $207.31B). The key difference: Novo Nordisk A/S is far larger — about 82.3× Danaos Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.76%). Which is the better fit depends on your goals.

DACNVO
Market Cap
$2.52B$207.31B
Sector
TechnologyHealth
52-Week High
$143.15$63.98
52-Week Low
$84.05$35.29
Enterprise Value
$2.50B$222.02B
Dividend Yield
2.6%3.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaos Corporation

Danaos Corporation (DAC) trades at $140.72, down 1.7% on the day, but maintains strong technical momentum with bullish moving averages and support at $139. The company demonstrates exceptional profitability with 51.26% net income margins and trades at attractive valuations including a P/E of 4.68 and P/B of 0.62. Recent earnings beats and a record $4.6 billion contracted revenue backlog highlight operational strength.

DAC presents compelling value with deep discount to book value and consistent earnings outperformance. Key risks include shipping industry cyclicality and capital expenditure requirements. Analyst sentiment is evenly split between Buy and Hold ratings, reflecting the stock's strong fundamentals against sector-specific headwinds.

Novo Nordisk A/S

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Danaos Corporation

Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.

Read more on DAC

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO